论文部分内容阅读
目的观察不同剂量盐酸吡格列酮(PIO)对糖尿病大鼠肾脏保护作用。方法将SD大鼠随机分为:糖尿病模型(DM)组,10、20和30mg/(kg.d)PIO干预组(DR1、DR2、DR3组)及正常对照(NC)组,每组各8只。8周末测血糖,HbA1c、UAlb、尿视黄醇结合蛋白(RBP)、尿沉渣nephrin(UNE)。留取肾组织观察病理变化及nephrin表达。结果 8周末UAlb、UNE、RBP、肾脏肥大指数(KI)、基底膜厚度(GBMT)、足突融合率(FPFR)DR1～3组均低于DM组,且DR2、3组低于DR1组(P<0.05);肾脏nephrin mRNA水平DM组>DR1～3组>NC组;肾脏nephrin蛋白NC组>DR1～3组>DM组;nephrin mRNA及蛋白在DR1～3组间比较差异无统计学意义。UNE与UAlb、KI呈正相关。结论 PIO可通过调节足细胞nephrin蛋白及mRNA表达、抑制UNE,起到保护肾脏的作用,有一定的剂量依赖性。
Objective To observe the protective effect of pioglitazone hydrochloride on the kidneys of diabetic rats. Methods SD rats were randomly divided into diabetic model group (DM), 10, 20 and 30 mg / (kg.d) PIO intervention groups (DR1, DR2 and DR3) and normal control group (NC) only. Blood glucose, HbA1c, UAlb, retinol-binding protein (RBP), urine nephrin (UNE) were measured on the 8th weekend. Renal tissue was collected to observe the pathological changes and nephrin expression. Results The levels of UAlb, UNE, RBP, KI, GBMT and FPFR at the 8th week were lower than those in the DM group, and were lower in the DR2,3 group than those in the DR1 group Nephrin mRNA level DM group> DR1 ~ 3 group> NC group; kidney nephrin protein NC group> DR1 ~ 3 group> DM group; nephrin mRNA and protein in DR1 ~ 3 group showed no significant difference . UNE and UAlb, KI was positively correlated. Conclusion PIO can regulate the expression of nephrin protein and mRNA in podocytes and inhibit the expression of UNE, which plays a role in protecting kidneys in a dose-dependent manner.